LUND, Sweden - Hansa Biopharma, a leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced a business update for the fourth quarter of 2023. The company expects to report SEK 50 million in total revenue, with SEK 43 million stemming from sales of its product Idefirix®. In clinical developments, Hansa's US ConfIdeS phase 3 trial for kidney transplantation has enrolled 101 patients, with a significant portion already randomized. Preliminary financials for the fourth quarter and full year 2023 reveal an operating loss of SEK 177 million for the quarter and SEK 790 million for the year, with research and development expenses reaching SEK 411 million. The full interim report for the fourth quarter of 2023 will be published on February 2, 2024.

Source: The North Africa Journal January 06, 2024 13:59 UTC